T-Therapeutics: Venture Capital Funding History
T-Therapeutics
To add a bio or update company history, please click update information.
News from T-Therapeutics


T-Therapeutics
5 Nov 2026
T-Therapeutics closes a £100m Series B led by Advent Life Sciences and British Business Bank to take its cancer and autoimmune treatments into clinical trials
T-Therapeutics is a biotechnology company developing T cell engager treatments based on human T cell receptors. Its drug programmes target cancer and autoimmune diseases.


T-Therapeutics
13 Nov 2025
T-Therapeutics secures £24m Series A extension with Tencent and BGF to develop T cell receptor therapeutics for cancer and autoimmune disease
T-Therapeutics develops next-generation T cell receptor therapies designed to target cancer and autoimmune disease, advancing bispecific molecules that selectively remove disease-driving immune cells while preserving healthy function.
T-Therapeutics
- Life Sciences
- Cambridge, United Kingdom
- £124m
- t-therapeutics.com
- Update Information
More venture news
- 13 Nov 2026

Oyster TherapeuticsOyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases
Series ALife Sciences - 10 Nov 2026

Neobe TherapeuticsNeobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours
SeedLife Sciences - 9 Nov 2026

PhaSER BiomedicalPhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases
GrantLife Sciences